Adial Pharmaceuticals to Host Conference Call Today at 11AM Eastern to Provide Clinical Update and Discuss Positive Business Developments
August 20, 2021 09:40 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Adial Pharmaceuticals Schedules Conference Call to Provide Clinical Update and Discuss Positive Business Developments
August 12, 2021 14:50 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Adial Pharmaceuticals Awarded U.S. and International Patents for the Treatment Of Alcohol and Opioid Use Disorders Using AD04
August 10, 2021 09:30 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Adial Pharmaceuticals Announces Closing of $5 Million Private Placement Priced at a Premium to Market
August 05, 2021 10:12 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Adial Pharmaceuticals Reports CEO Op-Ed Featured on Nasdaq.com
July 29, 2021 09:30 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., July 29, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for...
Adial Announces Positive Pre-Clinical Data for its Adenosine Pain Platform
July 14, 2021 14:00 ET
|
Adial Pharmaceuticals, Inc
Data merits further testing for pain reduction as a possible alternative to opioids Validation of Purnovate acquisition CHARLOTTESVILLE, Va., July 14, 2021 (GLOBE NEWSWIRE) -- Adial...
Adial Announces $5,000,000 Above Market Private Placement at $3.00 Per Share
July 07, 2021 10:11 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., July 07, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for...
The Phase 3 ONWARD™ Trial Meets its Screening Target and Nears Enrollment Completion
July 06, 2021 09:25 ET
|
Adial Pharmaceuticals, Inc
Study Drug Continues to Appear to be Well-Tolerated Patient Retention Currently Exceeds Expectations CHARLOTTESVILLE, Va., July 06, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc....
Adial Joins Russell Microcap® Index
June 28, 2021 09:45 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., June 28, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Adial Pharmaceuticals Provides Regulatory and Development Update
June 24, 2021 17:07 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., June 24, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for...